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Expression and distribution of epidermal growth factor in acute and
chronic renal allograft rejection. Epidermal growth factor (EGF) is a
fibrogenic cytokine with a possible role in chronic damage. EGF is also
involved in tubular regenerative response to injury. This study investigates
the expression and distribution of EGF in a rat model of renal allograft
rejection. EGF was localised in control kidneys to distal convoluted
tubules (DCT) and thick ascending ioop of Henle (TAL). Five days
post-transplantation EGF was diffusely distributed. In chronic rejection at
one, three and six months, damaged areas of allografts demonstrated faint
diffuse EGF staining, while well-preserved areas exhibited the normal
distribution pattern. PreproEGF mRNA was significantly reduced (P <
0.01) in acute rejection and in chronic rejection at three months to 28%
and 51% of normal, respectively. At six months values ranged from 16%
to 166% of normal kidneys, and were inversely correlated with tubular
damage (P < 0.01). PreproEGF mRNA was localized to DCT and TAL in
controls and in well preserved areas of the tissue in chronic rejection.
Thus, EGF would not appear to contribute to the development of injury
in chronic renal rejection. It may instead exert a protective effect on
tubular structures.
Chronic rejection is responsible for the loss over 10 years of
50% of grafts that survive the first year post-transplantation. This
rate of loss has not changed despite major improvements in
immunosuppressive therapy [1, 21. Further understanding of the
mechanisms of injury in this pathology is thus imperative for new
therapeutic strategies to be developed. Chronic renal rejection is
characterized clinically by proteinuria, hypertension and declining
renal function, and pathologically by inflammatory cell accumu-
lation, and by excess extracellular matrix deposition and prolifer-
ation of fibroblasts, smooth muscle and mesangial cells resulting
in interstitial fibrosis, vascular damage and glomeruloscierosis
[1—3]. These features of chronic rejection are consistent with the
involvement of fibrogenic growth factors such as epidermal
growth factor (EGF) in the pathophysiology of this disease.
Epidermal growth factor (EGF) is a 53-amino acid (6.2 kDa)
polypeptide which stimulates the proliferation and differentiation
of epidermal and epithelial cells as well as being mitogenic for
various other cell types in culture [4, 5]. EGF is produced in the
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kidney by the distal convoluted tubules (DCT) and the thick
ascending ioop of Henle (TAL) [6—8]. It is synthetized as a large
1207 amino acid preproEGF precursor [4, 5]. The precursor
contains a hydrophobic domain near the C-terminus, which
anchors it to the plasma membrane, followed by the mature EGF
sequence, and eight regions of partial sequence homology to
mature EGF in the extracellular domain. In the kidney this
precursor is not processed to its mature 6.2 kDa form, but is
accumulated in precursor form and cleaved from the membrane
by proteolytic enzymes releasing a 160 kDa EGF molecule [7, 9]
which has been identified in human urine. The lack of immuno-
reactivity of this secreted precursor with antipeptide antibodies
directed against the cytoplasmic C-terminus suggests that the
external EGF-containing domain of the membrane bound precur-
sor is released by proteolytic cleavage, although the exact nature
of the enzymatic activity is not known [9]. EGF is also released in
mature 6.2 kDa form from a granules of platelets [4, 5]. Binding
of EGF to its receptor activates a tyrosine kinase activity which
both auto-phosphorylates, and phosphorylates other substrates [4,
5]. The 160 kDa EGF precursor has been shown to be biologically
active, being capable of inducing the tyrosine autophosphoryla-
tion of EGF receptors in intact cells [9]. Receptors for EGF are
prominent in the antiluminal plasma membrane of proximal
tubules and cortical and inner medullary collecting ducts, and on
mesangial cells as well as on tubulointerstitial fibroblasts [10—14].
EGF is a potent mitogen for fibroblasts, epithelial and mesang-
ial cells, and could thus potentially contribute to the development
of interstitial fibrosis, glomerulosclerosis and vascular damage
characteristic of chronic renal allograft rejection. It also promotes
mesangial and smooth muscle cell contraction and stimulates
mesangial cell production of platelet-derived growth factor [11,
15], which in turn has been associated to the development of
injury in glomerulonephritis [16, 17] and renal allograft rejection
[18]. On the other hand, EGF is also thought to be important in
the maintenance of renal tubule integrity and in the tubular
regenerative response to injury [15, 19]. Altered expression and
distribution of EGF have been reported in models of acute
tubular injury and glomerulosclerosis, in which pathological fea-
tures similar to those seen in chronic rejection are evident
[20—26j. This study was undertaken to evaluate the possible
involvement of EGF in the pathophysiology of chronic renal
allograft rejection.
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Methods
Treatment groups
Chronic rejection model. The model of chronic renal allograft
rejection has been previously described [3]. Male, adult (3 to 6
months old) inbred Dark-Agouti (DA) (RT1a\l) and Albino-
Surgery (AS) (RT-11) rats were used, obtained from Monash
Animal Services. Briefly, recipient rats (AS) received one to three
transfusions of 1 ml heparinized DA blood, no later than six days
prior to transplantation, under cover of cyclosporin A (CsA; 5
mg/kg/day). Kidneys from untreated DA rats were transplanted
orthotopically into treated AS recipients. Recipient left renal
artery was "telescoped" into donor renal artery [27] and the vein
was reconstituted using an external cuff on the donor renal vein
[28]. Donor and recipient ureters were joined over a short stent.
The recipients' native kidneys were removed. Rats were killed five
days (N = 3), one month (N 5), three months (N =8) or six
months (N = 14) post-transplantation. Kidneys were removed and
processed for immunohistology, histopathology, RNA extraction
and in situ hybridization studies.
Acute rejection model. DA kidneys were transplanted orthotopi-
cally into untreated AS rats. Rats (N 7) were killed five days
after transplantation and rejecting allografts were retrieved.
Isografts. DA and AS isografts were included to control for
non-allogeneic injury resulting from the transplant procedure.
Isografts (N 6) were retrieved three months after transplanta-
tion.
Uninephrectomy. DA rats were uninephrectomized and a ure-
teric stent was implanted (as in grafts) to control for the effect of
uninephrectomy/stent implant. Uninephrectomized DA rats (N =
4) were killed three months after transplantation and the residual
kidney was retrieved.
Normal rat kidney (NRK). Six kidneys from normal rats were
used as controls.
Processing of graft upon nephrectomy
Kidneys were removed under anaesthesia, and rats were killed
immediately thereafter. Half of each kidney was immediately fixed
in 10% buffered formalin and embedded in paraffin for his-
topathological studies; 1/4 kidney was frozen in liquid nitrogen for
RNA extraction; 1/8 kidney was fixed in paraformaldehyde-lysine-
periodate (PLP) [29] for immunohistochemistry and 1/8 kidney
was embedded in O.C.T. compound (Miles, Elkhart, Indiana,
USA) and snap frozen in liquid nitrogen for in situ hybridization
studies.
Histopathology
Hematoxylin and eosin, periodic acid-Schiff, silver, Masson
trichrome and silver-Masson trichrome stains were performed on
formalin fixed tissue after paraffin embedding. Sections were
assessed by an independent pathologist and the severity of the
following changes was graded: (a) mononuclear leukocyte infil-
trate in the interstitium, mild to severe; (b) tubulointerstitial
damage: Tubular atrophy and diffuse and focal interstitial fibrosis
were graded from 0 to 4. Final tubulointerstitial damage scores
were obtained by averaging the score for tubular atrophy with the
mean interstitial fibrosis score (focal and diffuse); (c) glomerular
hypertrophy (0 to 4) (0-25%-50%-75%-100% of glomeruli in-
volved) and (d) Glomerulosclerosis 0 to 4 (0-25%-50%-75%-
100% of glomeruli involved), Observations were also made as to
other glomerular changes (cellularity, mesangiolysis, crescents
and ischemic changes) and vascular changes of rejection [3].
Immunohistochemistiy
Immunoreactive EGF was assessed on PLP fixed tissue sections
by a three-layer immunoperoxidase technique. Sections were
preincubated in 10% fetal calf serum (FCS-Cytosystems)/1O%
normal swine serum (Dako)/phosphate buffered saline (PBS) for
10 minutes to block nonspecific binding. All incubations were
performed at room temperature. Sections were then incubated
with rabbit anti-mouse EGF (Serotec) at a 1/500 dilution for one
hour. Slides were washed twice in PBS for five minutes and were
taken through graded alcohols before being immersed in Metha-
nol/0.03% H202 for 20 minutes to block endogenous peroxidase
activity. After two washes in PBS, peroxidase conjugated swine
anti-rabbit antibody (Dako) was applied to sections and incubated
for 30 minutes. This was followed by two washes in PBS and a
further incubation with rabbit peroxidase anti-peroxidase (PAP)
complex (Dako) for 30 minutes at room temperature and two
further PBS washes. Color was developed by the addition of
diaminobenzidine (Dako) substrate solution and slides were
counterstained in haematoxilyn and eosin and mounted using
DePeX mounting medium (Gurr). All staining runs included
appropriate negative controls without primary antibody as well as
sections of normal rat kidneys. The specificity of the rabbit
anti-mouse EGF antibody and its cross reactivity with rat EGF
was confirmed by the staining pattern obtained in normal rat
kidney, which agreed with other published studies [6—8].
Northern blot analysis
Total RNA was extracted from approximately 0.2 g to 0.6 g
kidney tissue snap frozen at nephrectomy using guanidine isothio-
cyanate and cesium chloride gradient centrifugation [30]. The
RNA was denatured by treatment with dimethylsulfoxide/glyoxal,
electrophoresed in a 1% agarose horizontal gel in phosphate
buffer and blotted onto nylon membrane (Hybond-N, Amer-
sham). Hybridization was carried out with a 400 bp double-
stranded mouse preproEGF cDNA probe [31], labeled with
32P-dCP using random primers (Megaprime, Amersham).
Quantitative variability of either isolation, transfer or loading of
RNA was controlled for by reprobing the blots with a 720 bp
cDNA probe for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Blots were prehybridized at 42°C for 4 to 16 hours
with buffer containing 0.1 to 0.2 mg/mi herring sperm DNA
(Sigma), 50% deionized formamide, 5 X SSPE buffer, 5 X Den-
hardt's reagent, 0.1% SDS, and hybridized overnight in the same
buffer containing radiolabeled probe (106 cpm/ml). Nonspecifi-
cally bound probe was removed by washing in 2x SSC/0.1% SDS
at room temperature for 20 minutes followed by 25 minutes in
0.2X SSC/0.1% SDS at 42°C. Blots were exposed for 4 to 24 hours
to Kodak XAR film at —80°C, using intensifying screens. The
levels of preproEGF and GAPDH mRNA expression were quan-
titated by scanning densitometry of the autoradiograph, using an
LKB Ultrascan II. Results are expressed as EGF/GAPDH ratios.
NRK standards were run on every blot to enable comparisons
between blots.
In situ hybridization
In situ hybridization was performed on some grafts at 3 m (N =
3) and 6 m (N = 4) post-transplantation and on NRK (N = 6).
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Tissue was snap frozen in OCT embedding medium (Miles,
Elkhart, Indiana, USA) at nephrectomy and stored at —80°C until
needed. Ciyostat sections (4 m) were cut and thawed onto slides
coated with 1% gelatine 0.25% formaldehyde and post-fixed in
4% glutaraldehyde in 0.1 M sodium phosphate with 20% ethylene
glycol at 4°C [32]. Slides were then rinsed in hybridization buffer
(600 m sodium chloride, 50 m sodium phosphate pH 7.0, 5.0
mM EDTA, 0.02% Ficoll, 0.02% bovine serum albumin, 0.02%
polyvinylpyrrolidone, 0.1% herring sperm DNA, 50% deionized
formamide) prehybridized for four hours at 37°C in hybridization
buffer, then dehydrated in two changes of absolute ethanol. The
preproEGF cDNA probe was labeled with 32P-dCTP using ran-
dom primers (Megaprime, Amersham), ethanol precipitated and
resuspended in hybridization buffer at approximately 7 X 106
cpm/20 p1. Twenty p1 of the labeled probe dilution was applied to
the sections on coverslips, and hybridization was performed
overnight at 37°C in a humidified chamber. Slides were then
washed individually at room temperature in 4 X SSC, followed by
immersion in 2 X SSC and 1 X SSC at room temperature and then
washed in 0.5 x SSC at 40°C for 45 minutes, with gentle agitation.
Slides were dehydrated in 70%, 90% and 2 x 100% ethanol, dried
and coated in 0.5% gelatine-0.05% chrome alum solution at 37°C
for 10 minutes. After air drying, sections were subject to emulsion
autoradiography with G5 emulsion (Ilford, Australia) desiccated
at 4°C and developed with Phenisol X-ray developer (Ilford) for
five minutes, followed by two minutes in acid stop bath and
Hypam X-ray Rapid Fixer (Ilford) for two to four minutes.
Sections were counterstained with hematoxylin and eosin and
examined with both bright field and dark field microscopy.
Probes
The preproEGF cDNA probe was provided by Dr. R.G.
Crawford; the GAPDH cDNA probe was synthetized by reverse
transcription-polymerase chain reaction of rat kidney RNA using
primers based on the published sequence [33]. The PCR product
was subcloned into pGEM-4Z.
Statistics
All statistical analyses were performed using SPSS for Win-
dows. Kruskall Wallis nonparametric ANOVA, Mann-Whitney U
test and Spearman correlations were performed.
Results
Histology
The evolution of the histological changes in this model of
chronic rejection and the main histological features of the acutely
rejecting grafts have been extensively described previously [31. In
the acute rejection model all kidney allografts five days after
transplantation showed extensive mononuclear leukocytic infil-
trate throughout the interstitium with moderate interstitial edema
and patchy tubular necrosis. In the chronic rejection model, these
features of acute rejection were also prominent at five days
post-transplantation, although injury was less severe. Following
resolution of this acute phase the typical changes of chronic
rejection developed over the subsequent three to six months
although the severity of damage varied between animals from
minimal (Fig. 1A) to extensive (Fig. 1 B-C). The features of
Fig. 1. Histology of the chronic renal allograft rejection model. Upon nephrec-
tomy, half of each kidney was fixed in 10% buffered formalin and embedded
in paraffin. Hematoxylin and eosin stains were performed. (A) Allograft at 3
months post-transplantation demonstrating mild interstitial infiltrate and
tubular dilatation. (B) Allograft at 3 months post-transplantation demonstrat-
ing focal interstitial infiltrate, marked tubular dilatation and flattened tubular
epithelium. (C) Severely damaged allograft at 6 months post-transplantation
demonstrating focal and diffuse interstitial infiltrate, tubular atrophy, inter-
stitial fibrosis and glomerulosclerosis. (Magnification A x 190; B-C X 310).
chronic rejection were mononuclear cell infiltrate, glomeruloscie-
rosis, vascular intimal thickening, interstitial fibrosis and tubular
atrophy, with severe tubular dilatation and flattening of the
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Northern blot analysis of preproEGF mRNA in acute and chronic
allograft rejection
3 months
Fig. 2. Evolution of tubulointerstitial damage. Hematoxylin and eosin,
periodic acid-Schiff, silver, Masson trichrome and silver-Masson trichrome
stains were performed on formalin fixed tissue after paraffin embedding.
Tubular atrophy and diffuse and focal interstitial fibrosis were graded from
0 to 4. Final tubulointerstitial damage scores were obtained by averaging
the score for tubular atrophy with the mean interstitial fibrosis score (focal
and diffuse).
tubular epithelium being evident in some rats (Fig. 1 B-C).
Tubulointerstitial injury was initially mild and focal but its severity
increased with time, becoming extensive and diffuse in some
animals by six months, although it still remained absent or very
mild (damage index below 0.5) in approximately 30% of kidneys
(Fig. 2).
Distribution of immunoreactive EGF
Immunohistochemical staining of NRK with anti-EGF antibody
demonstrated a strong EGF label on DC'T and TAL (Fig. 3 A, B),
in agreement with previous studies [6—8]. This was also the case
in uninephrectomized and isografted controls (Fig. 3C). In con-
trast, there was a strong diffuse EGF immunoreactivity through-
out the graft five days after transplantation in both the acute
rejection model (Fig. 3D) and in the tolerized rats. In the chronic
rejection model, the distribution of immunoreactive EGF was
dependent on the severity of chronic injury. One month post-
transplantation normal distribution was preserved in two al-
lografts which on histopathological evaluation exhibited no dam-
age (Fig. 3E); two other kidneys, with mild tubular damage and
evidence of glomerular hypertrophy, one of which also demon-
strated mild vascular damage, had a diffuse distribution of EGF.
At three and six months post-transplantation, allografts with very
mild or no tubular atrophy or interstitial fibrosis, demonstrated a
distribution of EGF similar to that of NRK. The remaining
allografts, with either moderate or severe chronic damage, had
weak diffuse EGF immunoreactivity throughout the tissue (Fig.
3F), although in some grafts positively labeled DCT were seen in
the relatively better preserved areas of the tissue.
Northern blot analysis of total renal RNA from grafts under-
going acute rejection (untreated rats at day 5 post-transplanta-
tion) demonstrated reduced levels of preproEGF mRNA to only
28% of the normal expression of this growth factor (P < 0.01;
Table 1; Fig. 4A). In contrast, in tolerized animals (chronic
rejection model) grafts at five days post-transplantation had
preproEGF levels which did not differ significantly from those of
normal rat kidney (Table 1, Fig. 4A).
The expression of preproEGF was examined in the chronic
rejection model at one, three and six months post-transplantation.
Table 1 lists the levels of preproEGF expression at those times
expressed as percentage of values in normal rat kidney. Expres-
sion of preproEGF was not significantly altered at one month
post-transplantation. By three months, however, it was signifi-
cantly reduced by half when compared to normal rat kidneys or to
control isografts and kidneys from uninephrectomized rats (Table
1; Fig. 4B). At six months post-transplantation the preproEGF
expression varied considerably between individuals: some of the
animals showed normal or even increased levels while others
retained depressed levels of preproEGFmRNA. Values at this
time point ranged from 16% to 166% of controls (Fig. 5).
Correlation studies between EGF expression and chronic damage
were performed to further understand this disparity between
individuals at six months after transplantation. The preproEGF!
GAPDH mRNA ratio was found to be inversely correlated with
tubulointerstitial damage (P < 0.01; Fig. 6). No correlation was
found with glomerular hypertrophy, glomerular sclerosis, or vas-
cular damage.
In situ hybridization
In situ hybridization studies demonstrated preproEGF mRNA
in the DCT and TAL in NRK (Fig. 7A) as previously described
[8]. Its expression in the chronic rejection model at three and six
months post-transplantation was dependent on the degree of
damage seen in the tissue, As shown in Fig. 7B, preproEGF
mRNA was expressed in well preserved areas of grafts, while none
was detected in areas with severe tubular damage.
Discussion
This study demonstrates altered expression and distribution of
EGF in acute and chronic renal allograft rejection. In acute
rejection, strong EGF immunoreactivity was seen, diffusely dis-
tributed throughout the tissue. This was accompanied by a
marked reduction in preproEGF mRNA levels. Intense diffuse
EGF staining was also observed at five days post-transplantation
in tolerized rats, but there was no significant reduction in pre-
proEGF mRNA. Unlike other growth factors, EGF is not ex-
pressed by any of the leukocyte subpopulations infiltrating the
acutely rejecting allograft [4, 5]. Thus, the increase in immunore-
active EGF would appear to reflect increased release of this
growth factor by platelets rather than enhanced gene expression,
in particular considering the reduction in preproEGF mRNA
demonstrated in the acute rejection model.
In this and in other models of tolerance [3, 34, 35], decreased
graft function and severe leukocyte infiltration are seen at early
times post-transplantation, which subside without treatment. It
has been suggested that the tolerant state may represent an
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Fig. 3. Distribution of immunoreactive EGF. Kidney sections were stained by an immunoperoxidase method using a polyclonal antibody specific for
EGF. (A, B) Normal rat kidney; (C) isograft, 3 months post-transplantation; (D) acute rejection model, renal allograft at 5 days post-transplantation;
(E) chronic rejection model, a well-preserved graft at 1 month post-transplantation; (F) Chronic rejection model, a severely damaged graft at 3 months
post-transplantation. (Magnification: A X 70; B X 310; C X 190; D X 310; E X 190; F X 310).
imbalance of the Th1/Th2 subsets in favor of the latter, since EGF has been shown to play a role in tubular repair [39, 40J. EGF
increased production of IL-4 and IL-b and decreased IL-2 and also has modulatory effects which may contribute to the establish-
TNFa have been reported [36—38]. The altered cytokine milieu in ment of the tolerant state: it has been shown to inhibit cell division
the tolerant rats may prevent the down-regulation of EGF pro- under certain conditions, transiently arresting A431 human epi-
duction seen in acute rejection and in other models of acute renal dermoid carcinoma cells in G-2 phase, although in most instances
injury [20—26]. Furthermore, the continued synthesis of EGF by it acts as a stimulator of mitosis, and it seems to inhibit organ
the tubules may be a factor contributing to their integrity, since growth in neonatal rats [26].
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Table 1. Northern blot analysis of preproEGF mRNA in acute and
chronic renal allograft rejection
Prepro-EGF
Treatment group
mRNA expressiona
%
Acute rejection day 5 28 3""
Chronic rejection model
DayS 70±16
lMonth 92± 11
3 Months 51 4
6 Months 88 13
Isografts 138 13
Uninephrectomy/stent 112 19
Data were analysed by Kruskall Wallis nonparametric ANOVA, and
pairs were compared by Mann-Whitney U test.
a Prcpro EGF/GAPDH ratio expressed as a percentage of results
obtained in NRK
bMean SEM
P < 0.01 as compared to normal rat kidney; P C 0.05 as compared to
Day 5 in the chronic rejection modeldP C 0.01 as compared to normal rat kidney, isografts and uninephrec-
tomy/stent
In the chronic rejection model, preproEGF mRNA was de-
creased twofold at three months post-transplantation when com-
pared to NRK, while at six months animals expressed a wide
spectrum of preproEGF mRNA levels, although in preliminary
studies with smaller numbers of animals we reported reductions
similar to those seen at three months [41]. This model demon-
strates a wide variability in the severity of damage seen in grafts at
three and six months post-transplantation, with some grafts
showing no tubular injury, interstitial fibrosis or glomeruloselero-
sis at those times [3]. There are also variable degrees of damage
in different areas of the same grafts. In all eases, preproEGF
mRNA was localized by in situ hybridization to preserved DCI'
and TAL in relatively less damaged areas of the kidney. The
reduction in preproEGF mRNA could simply reflect tubular
damage or could represent the response to an inhibitory signal. It
is unlikely that it reflects "dilution" of tubular RNA by RNA from
infiltrating inflammatory cells, proliferating flbroblasts, etc., since
no changes were seen in the chronic rejection model at five days
and one month post-transplantation, in which similar or more
severe infiltrates were seen [3]. The increase in preproEGF
mRNA levels seen in some animals at six months suggests the
changes may result from alternate down regulatory and up
regulatory signals, possibly depending on the degree of damage,
and the cytokine milieu present in the kidney at the different times
studied. Down-regulation of preproEGF mRNA has been de-
scribed in acute renal injury induced by isehemia, ureteral ob-
struction or by the administration of nephrotoxic agents [21, 23,
42] in which marked transient decrease ia preproEGF mRNA
transcription is evident despite lack of damage to DCT. Shaudies
and Johnson [43] have suggested that decreased preproEGF
mRNA transcription could be due to end-product inhibition.
However, this is unlikely in our model since tolerant rats at five
days post-transplantation exhibited increased immunoreactive
EGF accompanied by normal preproEGF mRNA levels.
Grafts with only very mild chronic damage had a preserved
distribution of immunoreactive EGF in DCT and TAL. In con-
trast, severely damaged grafts had decreased immunostainable
EGF: DCI' and TAL staining was absent, except in some rela-
lively well preserved areas of the graft, and the rest of the tissue
exhibited only weak diffuse staining. Toubeau et al [22, 44}
describe a redistribution of immunoreactive EGF in a model of
amikacin-induced tubular injury, in which they demonstrate prox-
imal tubule associated EGF immunoreactivity, possibly due to
up-regulation of EGF receptor expression and binding of "diffus-
able" EGF resulting from proteolytie processing of the membrane
bound precursor. No defined proximal tubule-associated EGF was
seen in our model. However, it has been suggested that the
"diffusable" EGF may be washed out during fixation and rinsing
of tissues, resulting in only membrane bound EGF being detected
by immunohistochemistry [25]. In compensatory renal hypertro-
phy after unilateral nephreetomy a redistribution of immunostain-
able EGF has been observed, from the luminal membrane to the
basolateral membrane of distal tubules [24], and a "juxtacrine"
action for this growth factor was suggested. This was not apparent
in our model.
The origin of the immunoreactive EGF described in this study
is not clear. An exogenous source is likely to be platelets, since
their accumulation and activation with consequent release of
growth factors is a prominent feature of allograft rejection [1, 2].
Increased soluble immunoreactive EGF has been described in
renal tissues after ischemia-indueed acute renal failure resulting
from proteolytie cleavage of membrane-associated precursors
[43}. This mechanism could contribute to the immunoreactive
EGF seen in the rejection models. However, in a model of
compensatory renal hypertrophy [24] increased quantities of
extractable "mature" EGF (6.2 kDa) were described, not affected
by the inclusion of aprotinin in kidney homogenates, rendering
unlikely the hypothesis that the increment in extractable "mature"
EGF can be explained by enhanced breakdown of EGF precursor,
and an exogenous source is favored. Further biochemical studies
are required to clarify the origin of the EGF seen in this model.
EGF has been shown to accelerate renal tubular regeneration
in rat models of gentamycin-induced tubular damage [40} and
mild or severe ischemie injury [45], while treatment with anti-EGF
antibody blocks tubular cell proliferation during compensatory
renal growth [46]. The paracrine role of the EGF produced by the
kidney on renal structures is controversial. It is not clear how renal
EGF, localized at the luminal plasma membrane of DCI and
TAL can bind to EGF receptors present on the basolateral
membrane of proximal tubules. However, it has been suggested
that intercellular tight junctions could be disrupted following
injury, and EGF could thus traverse to the basolateral surfaces
where it could interact with the EGF receptors [15]. At six months
post-transplant, an inverse correlation was demonstrated between
preproEGF mRNA levels and tubular damage. It is unlikely that
this simply reflects tubular atrophy, since there is an increase in
tubular damage with time, which should then result in progres-
sively lower EGF levels. Rather, the increased production of EGF
seen in animals with relatively well preserved tubules may repre-
sent an up regulation of this growth factor which could then exert
a paracrine effect in the regeneration of tubular structures.
Despite the fibrogenic nature of EGF, this growth factor does
not appear to contribute to the development of injury in chronic
renal allograft rejection, since increased severity of injury was not
accompanied by higher levels of either preproEGF mRNA or
immunoreaetive EGF. In contrast, we have demonstrated in-
creased expression of other fibrogenie growth factors such as
transforming growth factor /3 and platelet-derived growth factor
A
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Fig. 4. Northern blot analysis of preproEGF
mRNA in acute and chronic renal allograft
rejection. Total renal RNA samples (12 gIlane)
were isolated at different times post-
transplantation and Northern hybridization was
performed with prepro EGF and GAPDH
cDNA probes as described in the Methods. In
both (A) and (B) the upper panel shows
hybridization to prepro EGF: 4.9 kB band; the
lower panel shows hybridization to GAPDH,
1.4 kB band. (A) Northern blot demonstrating
reduced prepro EGF expression in acute
rejection and nonnal expression in tolerant rats
at 5 days post-transplantation. (B) Expression
of prepro EGF in chronic renal allograft
rejection at 1 and 3 months post-
transplantation. Lanes 6 and 9 (3 months post-
transplantation) represent two different RNA
samples from the same rat.
Fig. 5. PreproEGF mRNA levels at 6 months post-transplantation. Total
renal RNA samples were isolated and Northern hybridization was per-
formed with prepro EGF and GAPDH cDNA probes as described in the
Methods. The levels of prepro EGF and GAPDH mRNA were quanti-
tated by scanning densitometry of the autoradiograph. Results are ex-
pressed as EGF/GAPDH ratios. Units are arbitrary. All 6-month RNA
samples were run on the same Northern blot.
Tubulointerstitial damage
Fig. 6. Inverse correlation between EGF expression and tubular damage in
chronic renal aiograft rejection at 6 months post-transplantation. Ailografts
were removed at 6 months post-transplantation and processed for histopa-
thology and RNA extraction as described in the Methods. The tubuloin-
terstitial damage index (0 to 4) reflects tubular atrophy and interstitial
fibrosis. Northern hybridization was performed. The levels of prepro-EGF
and GAPDH mRNA were quantitated by scanning densitometry of the
autoradiograph. Results are expressed as EGF/GAPDH ratios. All units
are arbitrary. Data were analyzed by Spearman correlation. P < 0.01.
months post-transplantation. It is thus possible to speculate that
when present, EGF may exert a protective effect on tubular
structures, leading to enhanced graft survival. Further studies with
exogenous administration of EGF or EGF inhibitors should assist
in the clarification of its role in the pathophysiology of chronic
renal allograft rejection.
Acknowledgments
This work was presented in part at the XIIth International Congress of
Nephrology, Jerusalem, Israel, and at the 1993 Annual Scientific Meeting
of the Transplantation Society of Australia and New Zealand, Canberra,
5
Ia0
0
w
:i:a
a-
0
LL0
w
5
4
3
2
1
0
4
3
2
0
1 2 3
NRK 6 months
allografts
in this model (manuscript in preparation) which may well play a
more direct role in induction of chronic injury in this pathology.
Furthermore, this study demonstrates an association between
decreased renal expression of EGF and tubular injury at six
aet
1214 Stein-Oakley et al: EGF in renal allograft rejection
Fig. 7. Localization of preproEOF by in situ hybridization. In situ hybrid-
ization was performed as described in the Methods using a prepro EGF
cDNA probe labeled with 32P. (A) Normal rat kidney, (B) Chronic
rejection model at 3 months post-transplantation. (Magnification x 70).
Australia. Preliminary results have been published in extended abstract
form in Transplantation Proceedings [41]. The authors thank Ms. Karen
Verity and Dr. J. Penschow for their assistance in developing the
molecular biology techniques and Ms. Kirsty Baxter and Mr. Brian
Howden for performing the rat renal transplants.
Reprint requests to Alicia Stein-Oakley, Department of Medicine, Monash
Medical School, Alfred Hospital, Commercial Rd., Prahran, Victoria, 3181
Australia.
References
1. TILNEY NL, WHITLEY WD, DIAMOND JR, KuPIEc-WEGLIN5KI 3W,
ADAMS DH: Chronic rejection—An undefined conundrum. Trans-
plantation 52:389—398, 1991
2. PAUL LC, FELLSTROM B: Chronic vascular rejection of the heart and
the kidney—Have rational treatment options emerged? Transplanta-
tion 53:1169—1179, 1992
3. STEIN-OA.KLEY AN, JABLONSM P. TzANiois A, BAxTER K, HOWDEN
BO, MARSHALL VC, ThoMsoN NM: Development of chronic injury
and nature of interstitial infiltrate in a model of chronic renal allograft
rejection. Transplantation 56:1299—1305, 1993
4. BURGESS AW: Epidermal growth factor and transforming growth
factor a. Brit Med Bull 45:401—424, 1989
5. DAS M, RENGARAJU M, SAMANTA A: Epidermal growth factor. (Chapt
21), in Human Cytokines—Handbook for Basic and Clinical Research,
edited by AGGARwAL BB, GUTrERMAN JU, Boston, Blackwell Scien-
tific Publications, 1992, pp. 365—382
6. KA5SELBERG AG, ORnI DN, GRAY ME, STAHLMAN MT: Immunocy-
tochemical localisation of human epidermal growth factor/urogas-
trone in several human tissues. J Histochem Cytochem 33:315—322,
1985
7. RALL LB, PENSCHOW JD, NIALL HD, COGHLAN JP Mouse prepro-
epidermal growth factor synthesis by the kidney and other tissues.
Nature 313:228—231, 1985
8. SALIDO EC, YEN PH, SHAPIRO U, FISHER DA, BARAJAS L: In situ
hybridization of prepro-cpidermal growth factor mRNA in the mouse
kidney. Am Physiol Soc 256:F632—F638, 1989
9. MROCZKOWSKI B, REICH M: Identification of biologically active
epidcrrnal growth factor prccursor in human fluids and sccretions.
Endocrinology 132:417—425, 1993
10. CYBULSKY AV, 000DYER PR, CYR MD, MCTAvISH AJ: Eicosanoids
enhance epidermal growth factor receptor activation and proliferation
in glomerular epithelial cells. Am J Physiol 262:F639—F646, 1992
11. FIARRIS RC, HOOvER RL, JACOBSON HR, BADR KF: Evidence for
glomerular actions of epidermal growth factor in the rat. J Clin Invest
82:1028—1039, 1988
12. ALVAREZ RJ, SUN MJ, HAVERTY TP, lozzo RV, MYUERS JC,
NEILSON EG: Biosynthetic and proliferative characteristics of tubulo-
interstitial fibroblasts probed with paracrine cytokines. Kidney mt
41:14—23, 1992
13. DAMJANOY I, MILDNER B, KNOWLES BB: Immunohistochemical local-
ization of the epidermal growth factor receptor in normal human
tissues. Lab Invest 55:588—592, 1986
14. KIM DC, HANANO M, KANAI Y, OHNUMA N, SUGIYAMA Y: Localisa-
tion of binding sites for epidermal growth factor (EGF) in rat kidney:
Evidence for the existence of low affinity EGF binding sites on the
brush border membrane. Pharm Res 9:1394—1401, 1992
15. HARRIs RC: Potential physiologic roles for epidermal growth factor in
the kidney. Am J Kidney Dis 17:627—630, 1991
16. JOHNSON RJ, RAINES EW, FLOEGE JE, Y A, PRITZL P, ALPERS C, Ross
R: Inhibition of mesangial cell proliferation and matrix expansion in
glomerulonephritis in the rat by antibody to platelet-derived growth
factor. J Exp Med 175:1413—1416, 1992
17. FLOEGE 3, BURNS MW, ALPERS CE, YosHIMuIt A, PRITZL P,
GORDON K, SEIFERT RA, BOWEN-POPE DF, COUSER WG, JOHNSON
RJ: Glomerular cell proliferation and PDGF expression precede
glomerulosclerosis in the remnant kidney model. Kidney mt 41:297—
309, 1992
18. HIOOY N, DAVIDOFF A, BENEDIKSSON H, PAUL LC: Platelet-derived
growth factor receptor expression in chronic rejection of cardiac and
renal grafts in the rat, Transplant Proc 23:609—610, 1991
19. TAUB M, WANG Y, SZCZESNY TM, KLEINMAN HK: Epidermal growth
factor or transforming growth factor a is required for kidney tubulo-
genesis in matrigel cultures in serum-free medium. Cell Biol 87:4002—
4006, 1990
20. SAFIRSTEIN R, ZELENT AZ, PRICE PM: Reduced renal prepro-epider-
mal growth factor mRNA and decreased EGF excretion in ARF.
Kidney Int 36:810—815, 1989
21. STORCH 5, SAOGI 5, MEGYESI J, PRICE PM, SAFIRSTEIN R: Ureteral
obstruction decreases renal prepro-epidermal growth factor and
Tamm-Horsfall expression. Kidney mt 42:89—94, 1992
22. TOUBEAU G, NONCLERCO D, ZANEN J, LAMBRICHT P, TULKEN5 PM,
HEU5ON-STIENNON 3, LAURENT G: Distribution of epidermal growth
factor in the kidneys of rats exposed to amikacin. Kidney Int 40:691—
699, 1991
23. SAFIR5TEIN R, PRICE PM, SAGGI SJ, HARRIS RC: Changes in gene
expression after temporary renal ischemia. Kidney mt 37:1515—1521,
1990
24. MILLER SB, ROGERS A, Esms CE, HAMMERMAN MR: Increased distal
nephron EGF content and altered distribution of peptide in compen-
satory renal hypertrophy. Am J Physiol 262:F1032—F1038, 1992
25. NONCLERCO D, TOUBEAU G, LAURENT G, SCHAUDIES RP, ZftJ'EN 3,
HEU5ON-STIENNON JA: Immunocytological localisation of epidermal
growth factor in rat kidney after drug-induced tubular injury. Eur J
Morphol 3 1:65—71, 1993
26. VERSTREPEN WA, NOUWEN EJ, YUE XS, DE BROE ME: Attered
growth factor expression during toxic proximal tubular necrosis and
regeneration. Kidney Int 43:1267—1279, 1993
27. DUMINI FJ: A new microvascular "sleeve" anastomosis. J Surg Res
46:189—194, 1989
28. KAMADA N: A description of cuff techniques for renal transplantation
in the rat. Transplantation 39:93—95, 1985
Stein-Oakley et a!: EGF in renal allograft rejection 1215
29. HANCOCK WW, ATKINs RC: Immunohistological studies with mono-
clonal antibodies. Meth Enzymol 121:828—848, 1986
30. CHIRGWIN JM, PRZYBYLA AE, MACDONALD RJ, RUTrER WJ: Isola-
tion of biologically active ribonucleic acid from sources enriched in
ribonuclease. Biochemistiy 18:5294—5299, 1979
31. SCOI-F J, URDEA M, QUIROGA M, SANCHEZ-PESCADOR R, FONG N,
SELBY M, RUTrER WJ, BELL GI: Structure of a mouse submaxillary
messenger RNA encoding epidermal growth factor and seven related
proteins. Science 2:236—241, 1983
32. PENSCHOW JD, HARALAMBIDIS J, ALORED P, TREGEAR GW, COGHLAN
JP: Location of gene expression in CNS using hybridization histo-
chemistry. Meth Enzymol 124:534—549, 1986
33. FORT P, MARTY L, PIECHACZYK M, EL SABROUTI 5, DAN! C, JEAN-
TEUR C, BLANCHARD JM: Various rat adult tissues express only one
major mRNA species from the glyceraldehyde-3-phosphate-dehydro-
genase multigenic family. Nucl Acid Res 13:1431—1441, 1985
34. Hwrrr CW, BLACK KS, HARMAN JC, BEKO KR II, LEE HS, PATEL
AP, MARTIN DC: Partial tolerance in rat renal allograft recipients
following multiple blood transfusions and concomitant cyclosporine.
Transplantation 49:194—198, 1990
35. ARMSTRONG HE, BOLTON EM, MCMILLAN I, SPENCER SC, BRADLEY
JA: Prolonged survival of actively enhanced rat renal allografts despite
accelerated cellular infiltration and rapid induction of both Class I and
Class II MHC antigens. J Exp Med 164:891—907, 1987
36. DALLMAN MJ, SHIHO 0, PAGE TH, WooD KJ, MORRIS PJ: Peripheral
tolerance to alloantigen results from altered regulation of the inter-
leukin 2 pathway. J ExpMed 173:79—87, 1991
37. BUGEON L, CUTURI MC, PAINEAU J, CHABANNES D, SouuLLou JP
Decreased IFN-gamma and IL-2 expression in peripheral tolerance to
heart allografts with conserved granzyme A, perform and MHC
antigens mRNA expression. Transplant Proc 25:314—315, 1993
38. LOWRY RP, TucHI T, CREMI5I H, KONIECZNY B: Th2-like effectors
may function as antigen-specific suppressor cells in states of trans-
plantation tolerance. Transplant Proc 25:324—326, 1993
39. Mosizowrrz DW, SCHNEIDER AN, LANE PH, SCHMITZ PG, GILLESPIE
KN: Effect of epidermal growth factor in the rat 5/6 renal ablation
model. JAm Soc Nephrol 3:1113—1118, 1992
40. M0RIN NJ, LAURENT G, NONCLERCO D, TOUBEAU G, HEUSON-
STIENNON JA, BERGERON MG, BEAUCHAMP D: Epidermal growth
factor accelerates renal tissue repair in a model of gentamycin
nephrotoxicity in rats. Am J Physiol 263:F806—F811, 1992
41. STEIN-OAKLEY AN, TzANIDIs A, FULLER P, JABLONSKI P, THOMSON
NM: Chronic renal allograft rejection: Altered distribution and re-
duced expression of epidermal growth factor in a rat model. Trans-
plant Proc 25:2902, 1993
42. SAFIRSTEIN R, ZELENT AZ, PRICE PM: Reduced renal prepro-epider-
mal growth factor mRNA and decreased EGF excretion in ARF.
Kidney mt 36:810—815, 1989
43. SCHAUDIES RP, JOHNSON JP: Increased soluble EGF after ischemia is
accompanied by a decrease in membrane-associated precursors. Am J
Physiol 264:F523—F531, 1993
44. NONCLERCO D, TOUBEAU G, LAURENT G, SCHAUDIES RP, ZANEN J,
HEUSON-STIENNON JA: Immunocytological localization of epidermal
growth factor in the rat kidney after drug-induced tubular injury. Eur
JMorphol 31:65—71, 1993
45. FINE LG, HAMMERMAN MR, ABBOUD HE, FUSE H, MIZUNO I,
SAKAMOTO M, KATAYAMA T: Evolving role of growth factors in the
renal response to acute and chronic disease. [editorial] J Am Soc
Nephrol 48:261—264, 1992
46. KANDA 5, IGAWA T, SAKAI H, NOMATA K, KANETAKE H, SAITO Y:
Anti-epidermal growth factor antibody inhibits compensatory renal
hyperplasia but not hypertrophy after unilateral nephrectomy in mice.
Biochem Biophys Res Commun 187:1015—1021, 1992
